Cargando…

Augmented CD133 expression in distal margin correlates with poor prognosis in colorectal cancer

Pathological assessment of excised tumour and surgical margins in colorectal cancer (CRC) play crucial role in prognosis after surgery. Molecular assessment of margins could be more sensitive and informative than conventional histopathological analysis. Considering this view, we evaluated the distal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pradhan, Tapas, Padmanabhan, Krishnanand, Prasad, Manu, Chandramohan, K., Nair, S. Asha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533563/ https://www.ncbi.nlm.nih.gov/pubmed/30950180 http://dx.doi.org/10.1111/jcmm.14284

Ejemplares similares

Expression of CD133 is associated with poor prognosis in stage II colorectal carcinoma
por: Park, Youn Young, et al.
Publicado: (2019)

Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer
por: Hashimoto, Kousuke, et al.
Publicado: (2013)

Overexpression of Epcam and CD133 Correlates with Poor Prognosis in Dual-phenotype Hepatocellular Carcinoma
por: Zhang, Jie, et al.
Publicado: (2020)

CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies
por: Huang, Rongyong, et al.
Publicado: (2018)

STIL Endows Oncogenic and Stem-Like Attributes to Colorectal Cancer Plausibly by Shh and Wnt Signaling
por: Pradhan, Tapas, et al.
Publicado: (2021)

CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies: Erratum
Publicado: (2018)

CD133 Expression and the Prognosis of Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Chen, Shicai, et al.
Publicado: (2013)

A shorter distal resection margin is a surrogate marker of nodal metastasis and poor prognosis in distal gastrectomy for advanced gastric cancer
por: Takashima, Yusuke, et al.
Publicado: (2023)

Higher percentage of CD133(+ )cells is associated with poor prognosis in colon carcinoma patients with stage IIIB
por: Li, Chun-Yan, et al.
Publicado: (2009)

CD133 expression in cancer cells predicts poor prognosis of non-mucin producing intrahepatic cholangiocarcinoma
por: Cai, Xiaobo, et al.
Publicado: (2018)

CD133(+)CXCR4(+ )colon cancer cells exhibit metastatic potential and predict poor prognosis of patients
por: Zhang, Shan-shan, et al.
Publicado: (2012)

CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: A clinical and experimental study
por: HE, AINA, et al.
Publicado: (2012)

High CD133 Expression in the Nucleus and Cytoplasm Predicts Poor Prognosis in Non-Small Cell Lung Cancer
por: Huang, Minjie, et al.
Publicado: (2015)

Promoter hypermethylation of CD133/PROM1 is an independent poor prognosis factor for head and neck squamous cell carcinoma
por: Hu, Zele, et al.
Publicado: (2020)

The Potential Role of CD44 and CD133 in Colorectal Stem Cell Cancer
por: Abdou Hassan, Wael, et al.
Publicado: (2022)

CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma
por: Fan, Linni, et al.
Publicado: (2011)

Cancer stem cells CD133 and CD24 in colorectal cancers in Northern Iran
por: Nosrati, Anahita, et al.
Publicado: (2016)

Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer
por: WANG, CHUNXIA, et al.
Publicado: (2012)

Effects of Metformin on CD133+ Colorectal Cancer Cells in Diabetic Patients
por: Zhang, Yanfei, et al.
Publicado: (2013)

Immunohistochemical Expression of the Stem Cell Marker CD133 in Colorectal Carcinoma
por: Suman, Sweta, et al.
Publicado: (2023)

Oxytetracycline have the therapeutic efficiency in CD133(+) HCC population through suppression CD133 expression by decreasing of protein stability of CD133
por: Song, Yeonhwa, et al.
Publicado: (2018)

CD133 and Ki-67 expression is associated with gastrointestinal stromal tumor prognosis
por: LU, CANRONG, et al.
Publicado: (2013)

An Overview of CD133 as a Functional Unit of Prognosis and Treatment Resistance in Glioblastoma
por: Joyce, Thomas, et al.
Publicado: (2023)

CD44/CD133-Positive Colorectal Cancer Stem Cells are Sensitive to Trifluridine Exposure
por: Tsunekuni, Kenta, et al.
Publicado: (2019)

Low tumour cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers
por: Palmqvist, R, et al.
Publicado: (1999)

CD133 expression is an independent prognostic marker for low survival in colorectal cancer
por: Horst, D, et al.
Publicado: (2008)

Prognostic role of CD133 expression in colorectal cancer: a meta-analysis
por: Wang, Ke, et al.
Publicado: (2012)

Expression of CD133, E-cadherin and WWOX in colorectal cancer and related analysis
por: Sun, Wenwen, et al.
Publicado: (2017)

Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells
por: Friel, Anne M, et al.
Publicado: (2010)

Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations
por: Grasso, Carole, et al.
Publicado: (2016)

Stem Cell Markers CXCR-4 and CD133 Predict Aggressive Phenotype and Their Double Positivity Indicates Poor Prognosis of Oral Squamous Cell Carcinoma
por: Caspa Gokulan, Ravindran, et al.
Publicado: (2021)

APEX1 predicts poor prognosis of gallbladder cancer and affects biological properties of CD133(+) GBC-SD cells via upregulating Jagged1
por: Wu, Zhengchun, et al.
Publicado: (2023)

Downregulation of miR‐133b predict progression and poor prognosis in patients with urothelial carcinoma of bladder
por: Chen, Xiaonan, et al.
Publicado: (2016)

Prognostic value of CD133(+) CD54(+) CD44(+) circulating tumor cells in colorectal cancer with liver metastasis
por: Fang, Chao, et al.
Publicado: (2017)

CD133 Expression and Identification of CD133/nestin Positive Cells in Rhabdomyosarcomas and Rhabdomyosarcoma Cell Lines
por: Sana, Jiri, et al.
Publicado: (2011)

Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma
por: Oliver, Jaime Antonio, et al.
Publicado: (2014)

CD133-targeted oncolytic adenovirus demonstrates anti-tumor effect in colorectal cancer
por: Sato-Dahlman, Mizuho, et al.
Publicado: (2017)

DNA mismatch repair and CD133-marked cancer stem cells in colorectal carcinoma
por: Cheah, Phaik-Leng, et al.
Publicado: (2018)

ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?
por: CZECZKO, Leticia Elizabeth Augustin, et al.
Publicado: (2021)

ARE STEM CELL MARKER EXPRESSION AND CD133 ANALYSIS RELEVANT TO DIFFERENTIATE COLORECTAL CANCER?
por: CZECZKO, Leticia Elizabeth Augustin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a1nhi99bh7rbp04d6rq162q1te